iBio Unveils Plans for Public Offering

iBio's Public Offering Announcement: iBio, Inc. has initiated an underwritten public offering of pre-funded warrants and Series G and H warrants for purchasing shares of its common stock, subject to market conditions.

Use of Proceeds: The company plans to utilize the net proceeds from the offering to advance its preclinical cardiometabolic programs and other pipeline assets, as well as for general corporate purposes.

Management of the Offering: Leerink Partners is the lead bookrunning manager for the offering, with LifeSci Capital and Oppenheimer & Co. also involved as bookrunning managers.

Forward-Looking Statements: The announcement includes forward-looking statements regarding the offering and iBio's future capabilities in developing biopharmaceuticals, emphasizing that actual results may vary due to various risks and uncertainties.